FUL

Rating neutralAI MemoPost-earnings T+3

H.B Fuller

As of 2026-09-28/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FY2026 guidance depends on pricing and margin execution • 2026-11-28

Base target: $56 / p=45% prob

Biggest risk

Revenue missed the cited consensus, underlying volume declined, and the EBITDA guidance midpoint did not rise. After the print, Baird cut its target from $75 to $65 while retaining Outperform, and Citi cut its target from $75 to $63 while retaining Buy. These revisions temper the positive operating read-through. Sources: Baird revision, Citi revision.

Invalidation

Break below $39 or thesis failure.

What would change my mind?

Q3 adjusted EPS beat the cited consensus by $0.05, pricing offset volume declines, and adjusted EBITDA margin approached 20%. Continued savings and a successful AMS close could support a rerating [#PR-2026-09-23].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-28

Base target

$56

p=45%

Bull target

$67

p=30%

Bear target

$39

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quantum Leap savings versus persistent volume weakness
Q3 adjusted EPS beat the cited consensus by $0.05, pricing offset volume declines, and adjusted EBITDA margin approached 20%.
Continued savings and a successful AMS close could support a rerating [#PR-2026-09-23].

BearKey bullets

AMS closing, financing and integration could complicate deleveraging; the Q3 10-Q excerpt identifies related financing costs [#10-Q-2026-09-24].
Post-earnings analyst target cuts show that stronger reported margins have not resolved forward-return concerns.
Q3 organic growth relied on 7.4% pricing while volume declined; sustained customer demand improvement remains unproven [#PR-2026-09-23].

WatchKey bullets

FY2026 guidance depends on pricing and margin execution

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $56 (p=45%)

Target spread vs base: +20% / -30%

Scenario probabilities

Bull Target: $67 (p=30%)Base Target: $56 (p=45%)Bear Target: $39 (p=25%)

Commentary

The T+3 read is mixed: an EPS beat and margin expansion were offset by a revenue miss, declining volume and target cuts. Trusted coverage described a modest decline in the first post-release trading session; the packet's September 25 adjusted-close anchor is $50.06. Broader estimate-revision data and reliable social, options and short-interest measures are unavailable, so the zero-valued sentiment fields are placeholders, not measured readings. Sources: earnings comparison, post-release reaction.

As of 2026-09-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Quantum Leap savings versus persistent volume weakness

Scenarios

Bull Target (Scenario probability)

$67 / p=30% prob

Base Target (Scenario probability)

$56 / p=45% prob

Bear Target (Scenario probability)

$39 / p=25% prob

Analysis 2026-09-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-28
FY2026 guidance depends on pricing and margin execution
Q3 adjusted EPS of $1.52 exceeded the $1.47 consensus reported by MarketBeat, but $938 million of revenue missed its $945.59 million estimate. Pricing contributed 7.4% while volume declined; adjusted EBITDA margin reached 19.9%. Management narrowed FY2026 adjusted EBITDA guidance to $655 million–$670 million and adjusted EPS guidance to $4.70–$4.85. The EBITDA midpoint is unchanged from Q2 guidance, so this is not a substantial guidance upgrade [#PR-2026-09-23] [#SEC-8K-2026-09-24]. Sources: company Q3 release, company Q2 release, consensus comparison.
Prob 65.00% • Move 7.00% • Priced-in 55.00%
EVENT2026-12-31
Pending AMS acquisition and financing
Management anticipates closing the Advanced Medical Solutions acquisition before year-end, but it has not reported completion. The deal could improve healthcare exposure; financing and integration could delay deleveraging. The Q3 10-Q excerpt identifies acquisition-related debt-extinguishment and bridge-financing costs [#PR-2026-09-23] [#10-Q-2026-09-24]. Source: company Q3 release.
Prob 70.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Quantum Leap savings versus persistent volume weakness
2027-12-31
Pricing and restructuring savings drove Q3 margin expansion, supporting the self-help thesis. Sustained gains require savings to outweigh lower customer volumes and elevated input costs; Q3 net working capital rose to 18.5% of annualized revenue as inventory was built for supply continuity [#PR-2026-09-23]. Source: company Q3 release.
Prob 60% • Move 10% • Priced-in 45%

Risks

AMS closing, financing and integration could complicate deleveraging; the Q3 10-Q excerpt identifies related financing costs [#10-Q-2026-09-24].
Post-earnings analyst target cuts show that stronger reported margins have not resolved forward-return concerns.
Q3 organic growth relied on 7.4% pricing while volume declined; sustained customer demand improvement remains unproven [#PR-2026-09-23].
Raw-material disruption and inventory investment could pressure cash conversion; Q3 net working capital rose 150 basis points year over year [#PR-2026-09-23].
The Q3 10-Q and FY2025 10-K excerpts identify ongoing litigation and product claims related to a divested business [#10-Q-2026-09-24] [#10-K-2026-01-22].

Peers

Symbol	Summary
KWR	Similar-sized specialty-chemicals candidate, but industrial process fluids are not a direct adhesives business; use only as a loose operating comparison. Source: Quaker Houghton investor relations.
RPM	More relevant operating comparison for sealants, adhesives and building products, but its diversified coatings portfolio limits valuation comparability. Source: RPM company overview.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-28

Loading AI feed…

Symbol

Summary

KWR

Similar-sized specialty-chemicals candidate, but industrial process fluids are not a direct adhesives business; use only as a loose operating comparison. Source: Quaker Houghton investor relations.

RPM

More relevant operating comparison for sealants, adhesives and building products, but its diversified coatings portfolio limits valuation comparability. Source: RPM company overview.